With Amgen's (AMGN) recent decisions to acquire emerging market generic drug companies, partner with Watson (WPI) for biosimilars development, and out-license non-core drugs to AstraZeneca (AZN),
there's really no more dispute that Amgen has graduated to the ranks of
Big Pharma. This isn't a bad thing; it just changes how investors ought
to approach and value the company. While there are patent and
competitive risks to this name, all in all it seems Wall Street has
taken an overly dim view of its prospects.
Read the full article here:
Amgen Looking, Thinking, And Acting More Like A Pharma Co.
No comments:
Post a Comment